Tumor samples were fixed in formalin and embedded in paraffin (FFPE) and 4 μm thick sections were cut for staining. A pathologist (AW) evaluated hematoxylin and eosin (H&E) stained slides from each FFPE block. MIF staining was performed on the BOND RX
m Research Stainer (Leica Biosystems). The MIF panel consisted of the following antibodies (clone, company, and opal fluorophores): TIM3 (
D5D5R™, Cell Signaling, Opal 540), CTLA4 (UMAB249, Biocare Medical, Opal 570), OX40 (E9U7O, Cell Signaling, Opal 520), PD-L1 (
E1L3N, Cell Signaling, Opal 620), LAG3 (D2G4O, Cell Signaling, Opal 650), pancytokeratin (
AE1AE3, Agilent DAKO, Opal 690). All AKOYA reagents used for MIF staining are part of a detection kit (NEL821001KT).
Spectral DAPI (AKOYA Biosciences) was applied once slides were removed from the BOND. They were cover slipped using an aqueous method and
Diamond antifade mounting medium (Invitrogen, ThermoFisher). Slides were imaged on the Vectra
® Polaris Automated Quantitative Pathology Imaging System (AKOYA Biosciences). Spectral unmixing, tissue and cell segmentation, and cell phenotyping were performed on inForm
® Software v2.4.8 (AKOYA Biosciences).
Hellström I., Ledbetter J.A., Scholler N., Yang Y., Ye Z., Goodman G., Pullman J., Hayden-Ledbetter M, & Hellström K.E. (2001). CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer. Proceedings of the National Academy of Sciences of the United States of America, 98(12), 6783-6788.